Prelude Therapeutics Inc
NASDAQ:PRLD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Prelude Therapeutics Inc
Other Non-Cash Items
Prelude Therapeutics Inc
Other Non-Cash Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Non-Cash Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Prelude Therapeutics Inc
NASDAQ:PRLD
|
Other Non-Cash Items
$13.1m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Other Non-Cash Items
$9.5B
|
CAGR 3-Years
12%
|
CAGR 5-Years
2%
|
CAGR 10-Years
25%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other Non-Cash Items
$2.5B
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
10%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Other Non-Cash Items
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other Non-Cash Items
$1.2B
|
CAGR 3-Years
26%
|
CAGR 5-Years
41%
|
CAGR 10-Years
17%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other Non-Cash Items
$183.1m
|
CAGR 3-Years
-48%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-10%
|
|
Prelude Therapeutics Inc
Glance View
Prelude Therapeutics, Inc. operates as a cancer drug discovery company. The company is headquartered in Wilmington, Delaware and currently employs 116 full-time employees. The company went IPO on 2020-09-25. The firm is focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers. Its drug discovery engine is designed to identify biological targets and create new chemical entities (NCEs). Its pipeline includes six programs, including methyltransferases, kinases, protein-protein interactions and targeted protein degraders. The firm is developing therapies in both solid tumors and hematological malignancies, such as adenoid cystic carcinoma (ACC), homologous recombination deficient positive (HRD+), cancers, myelofibrosis (MF) and glioblastoma multiforme (GBM), amongst others. The Company’s product candidates include PRT543, PRT811, PRT1419, PRT2527, PRT-SCA2 and PRT-K4.
See Also
What is Prelude Therapeutics Inc's Other Non-Cash Items?
Other Non-Cash Items
13.1m
USD
Based on the financial report for Dec 31, 2025, Prelude Therapeutics Inc's Other Non-Cash Items amounts to 13.1m USD.
What is Prelude Therapeutics Inc's Other Non-Cash Items growth rate?
Other Non-Cash Items CAGR 5Y
19%
Over the last year, the Other Non-Cash Items growth was -29%. The average annual Other Non-Cash Items growth rates for Prelude Therapeutics Inc have been -24% over the past three years , 19% over the past five years .
